Randomized phase II study of gemcitabine plus S-1 combination therapy vs. S-1 in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG0805).

Abstract	A randomized Phase II selection design trial comparing gemcitabine plus S-1 combination therapy with S-1 monotherapy for chemo-naïve unresectable or recurrent biliary tract cancer patients was started in Japan. The aim of this trial is to evaluate the efficacy and safety of the two regimens and to determine which is more promising as a test arm regimen to be compared with the current standard regimen, gemcitabine plus cisplatin, in a subsequent Phase III trial. Patients with unresectable or recurrent biliary tract cancer are randomized to either gemcitabine plus S-1 combination therapy arm or S-1 monotherapy arm. A total of 100 patients will be accrued for this study from 18 institutions over 1 year. The primary endpoint is the proportion of 1-year overall survival, and the secondary endpoints are progression-free survival, response rate and adverse events.
Authors	Atsuo Takashima, Chigusa Morizane, Hiroshi Ishii, Kenichi Nakamura, Haruhiko Fukuda, Takuji Okusaka, Junji Furuse
Journal	Japanese journal of clinical oncology (Jpn J Clin Oncol) Vol. 40 Issue 12 Pg. 1189-91 (Dec 2010) ISSN: 1465-3621 [Electronic] England
PMID	20630899 (Publication Type: Clinical Trial, Phase II, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)
Chemical References	Antimetabolites, Antineoplastic Drug Combinations Deoxycytidine S 1 (combination) Tegafur Oxonic Acid Gemcitabine
Topics	Administration, Oral Adult Aged Antimetabolites, Antineoplastic (administration & dosage, adverse effects, therapeutic use) Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use) Biliary Tract Neoplasms (drug therapy) Deoxycytidine (administration & dosage, adverse effects, analogs & derivatives, therapeutic use) Disease-Free Survival Drug Administration Schedule Drug Combinations Female Humans Infusions, Intravenous Japan Male Middle Aged Oxonic Acid (administration & dosage, adverse effects, therapeutic use) Patient Selection Sample Size Survival Analysis Tegafur (administration & dosage, adverse effects, therapeutic use) Treatment Outcome Gemcitabine

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!